CapsoVision, Inc. (NASDAQ:CV) Short Interest Up 35.2% in March

CapsoVision, Inc. (NASDAQ:CV) saw a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 553,348 shares, a growth of 35.2% from the February 26th total of 409,160 shares. Based on an average trading volume of 199,118 shares, the short-interest ratio is currently 2.8 days. Approximately 1.2% of the shares of the company are sold short.

CapsoVision Stock Performance

CapsoVision stock traded down $0.16 during midday trading on Monday, reaching $7.35. 23,653 shares of the company were exchanged, compared to its average volume of 439,177. The firm’s 50-day simple moving average is $5.58 and its 200-day simple moving average is $6.29. CapsoVision has a 1 year low of $3.43 and a 1 year high of $15.37. The company has a market capitalization of $344.30 million and a price-to-earnings ratio of -3.36.

CapsoVision (NASDAQ:CV) last released its earnings results on Thursday, March 26th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $3.92 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CV. New York State Common Retirement Fund purchased a new position in shares of CapsoVision during the 3rd quarter worth $34,000. Deutsche Bank AG purchased a new stake in shares of CapsoVision in the fourth quarter valued at $47,000. Wells Fargo & Company MN lifted its position in CapsoVision by 66.4% during the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock worth $67,000 after buying an additional 2,508 shares during the period. Citadel Advisors LLC purchased a new position in CapsoVision during the third quarter worth about $115,000. Finally, Virtu Financial LLC acquired a new stake in CapsoVision in the 4th quarter worth about $128,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CV shares. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. Wall Street Zen raised CapsoVision to a “hold” rating in a report on Saturday, January 10th. Finally, Benchmark lowered their target price on CapsoVision from $14.00 to $10.00 and set a “speculative buy” rating on the stock in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CapsoVision presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.